Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to approximately 50 countries internationally.

Based in the UK, the brand was launched in 2005 by Charles Rolls and Tim Warrillow to provide high quality, natural mixers which could accompany the growing demand for premium spirits. The Group now sells a range of 12 differentiated flavours to hotels, restaurants, bars and cafes ("On Trade") as well as supermarkets and off-licenses for retail purchase ("Off Trade"). Approximately 70 per cent. of the Group's sales were derived from outside of the UK in FY13 with the key overseas markets being the US, Spain, and Belgium.

The Group's mixers are designed to be accompaniments for alcoholic spirits or used in cocktails, although they can also be consumed on their own. Since 2005, the Company has launched at least one new product a year, which includes 4 variants of tonic water, 2 variants of ginger beer, 3 variants of lemonade, and one variant each of ginger ale, soda water and cola.

7 November 2014
Admission to AIM and first day of dealings


http://www.fever-tree.com/

was just about to post that :-)

Never rated this lot anyway 😀

no doubt because you never bought them

exactly so skinny ..... bounce from 200 sma; you'ld have to have moved fast and bravely to catch at the bottom though

though restaurant and pub figures may be down, don't forget that FEVR has a lot of other exposure through the supermarkets and even airlines

Sharecast -

RBC slashes Fevertree target price on competitive threat from Schweppes




FEVERTREE DRINKS
1,911.00
16:35:24 02/11/17
-5.63%
-114.00
Analysts at RBC Capital Markets slashed their target price on shares of Fevertree ahead of the re-launch of Schweppes's more premium 1783 brand and in light of the recent acceleration in the rate of organic growth in the company's sales in the UK market to over 60% since the backhalf of 2016.
They conceded the company's "strong execution" and the "extraordinary" performance of its premium gin category but were wary of reports that Schweppes was set to make the largest ever investment - roughly £6.6m according to Marketing Week - in the above brand.
Somewhat ironically too, Fevertree's success meant its growth profile was also more exposed to such a threat, what with sales in Britain expected to account for 45% of the total in fiscal year 2017 for a market share of 30%.
Hence, RBC lowered its projections for the company's rate of organic sales growth between 2017 to 2019 in the UK from 60%, 20% and 14% to 50%, 10% and 10%, respectively.
In turn, organic group sales were now seen rising by 44%,. 19% and 18%, down from 49%, 24% and 19%, respectively.
The broker also trimmed its estimates for the group's EBIT margins for the next three years by 50 basis points as a result of its forecasts for increased spending in advertising and publicity in the UK market.
All told, the result of those revisions drove its target price down from 2,400p to 2,000p and resulted in the analysts downgrading their recommendation on the stock from 'outperform' to 'sector perform'.

Looks like Schweppes are going to take them on with their own brand, opposed to a buy out.

536. Lack of sense of humour alert!

Schweppes rebrands tonics and creates new flavours

i banked the very substantial profit on 20% of my holding, putting ~50% of the proceeds into VSR

Or VRS even

Or...... could be a Canadian mining company called Vanstar?

def VRS - an atypical typo for MrC :-)

or - Vibratory Stress Relieving Company Ltd

cynic is too laid back for their products skinny

Wakey wakey ,Trading update and good rise so far .

FEVR
bear bums bitten badly - hohoho!
fy trading forecast materially ahead of expectations

Shore Capital comment:
"We are upgrading our forecasts which are already ahead of consensus going into today’s statement. FY2017F revenue will increase to £158m from £154m but the leverage impact through the income statement is strong with PBT increasing to £53.3m from £50.5m. This equates to an increase in EPS of 6% to 37.4p from 35.4p.

In terms of valuation this puts Fevertree on a FY2017F PER of 51.5x with an EV/EBITDA ratio of 42.2x and a 0.6% yield. We believe the valuation remains full although we expect the share to gain back some of the recent lost ground. The key point for us looking forward now is assessing the strength of momentum alongside the leverage potential with today’s upgrade achieved with a lower level of market spend than expected. This could suggest stronger profitability than is currently suggested in consensus expectations ahead of the delivery of strong than expected revenue growth. For now we retain our HOLD recommendation."

Trading Update
RNS
RNS Number : 7183V
Fevertree Drinks PLC
07 November 2017
 
 
7th November 2017
 
Fevertree Drinks plc ("Fever-Tree")
 
Trading Update
 
 
Fever-Tree, the world's leading supplier of premium carbonated mixers, today announces a trading update ahead of the year ending 31 December 2017.
 
The Board is pleased to announce that the strong growth seen in the first six months of 2017 has continued during the second half.  Fever-Tree's pioneering focus on taste and ingredients continues to transform the global mixer category driving growth across all the Group's regions. The exceptional performance in the UK, the Group's largest market, has been particularly impressive with the rate of sales growth and momentum strong across both the on and off trade. The mixer category is now the fastest growing category across the UK soft drinks sector with Fever-Tree responsible for 97% of the value growth in retail over the last 12 months.
 
Given the strong performance in the period to date, the Board anticipates that the results for the full year ending 31 December 2017 will be materially ahead of current market expectations